Clinical Trial Update: Paliperidone Palmitate Flexible Dosing in Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating flexible dosing of paliperidone palmitate for schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Invega Sustenna (paliperidone palmitate) (paliperidone palmitate)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED